Photo of Kathleen Mahoney,  MD, PhD

Kathleen Mahoney, MD, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 735-2063


kmmah5@bidmc.harvard.edu

Kathleen Mahoney, MD, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending, Medicine, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

At the Beth Israel Deaconess Medical Center. I have witnessed the clinical benefits that immune therapies (such as high dose interleukin 2, ipilimumab, and PD-1:PD-L1 blocking agents) can have in my patients. My current research focus in the laboratory is to better understanding the biology of immune checkpoints in tumors and how to augment patients’ immune response to effectively attack their tumors.

Publications

Powered by Harvard Catalyst
  • Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney KM, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye H. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin Cancer Res 2017. PubMed
  • Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 2017; 5:480-492. PubMed
  • Bu X, Mahoney KM, Freeman GJ. Learning from PD-1 Resistance: New Combination Strategies. Trends Mol Med 2016; 22:448-51. PubMed
  • Mahoney KM, Jacobus S, Bhatt RS, Song J, Carvo I, Cheng SC, Simpson M, Fay AP, Puzanov I, Michaelson MD, Atkins MB, McDermott DF, Signoretti S, Choueiri TK. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2016. PubMed
  • Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, Hodi FS, Sharpe AH, Signoretti S, Rodig SJ, Freeman GJ. PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res 2015; 3:1308-15. PubMed
  • Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14:561-84. PubMed
  • Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015. PubMed
  • Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Huntingt) 2014; 28 Suppl 3:39-48. PubMed
  • Mahoney KM, Ackerman A, Cho DC, McDermott DF, Peters T, Atkins MB. Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. J Clin Oncol 2013; 31:e364-6. PubMed
  • McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 2011; 117:5461-8. PubMed
  • Mahoney KM, Petrovic N, Schacke W, Shapiro LH. CD13/APN transcription is regulated by the proto-oncogene c-Maf via an atypical response element. Gene 2007; 403:178-87. PubMed